Form 4: Repare Therapeutics Director Ann D. Rhoads Acquires Stock Options

Director Ann D. Rhoads of Repare Therapeutics Inc. reports the acquisition of stock options.

Summary

• On June 17, 2024, Ann D. Rhoads, a director of Repare Therapeutics Inc., acquired stock options.
• The stock options grant the right to buy 27,200 common shares at an exercise price of $3.80.
• The options vest in equal monthly installments over twelve months from the grant date, contingent upon continued service.
• Following the transaction, Rhoads directly owns 27,200 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. The director's acquisition could be seen as a positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of compensation packages.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive and director compensation packages.
• The vesting schedule of 12 months is fairly standard, aligning with typical industry practices for incentivizing long-term commitment.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future.

Key Dates